<p>根据 MUFG 证券 EMEA plc 最近向证券交易委员会的披露，该公司在 2023 年第一季度将其在辉瑞公司（NYSE:PFE - 免费报告）的持股比例降低了 54.6%。在此期间，该基金出售了 476,100 股后，持有 395,999 股该生物制药公司的股票。根据其最近向证券交易委员会的备案，MUFG 证券 EMEA plc 在辉瑞的持股价值为 10,035,000 美元。</p>
<ul>
<li>医疗保健股票估值触底，3 只股票有望反弹</li>
</ul>
<p>其他对冲基金和机构投资者最近也买卖了该公司的股票。先锋集团在第一季度将其在辉瑞的持股比例增加了 0.9%。先锋集团目前拥有 523,165,127 股该生物制药公司的股票，价值为 13,257,004,000 美元，此前在此期间又购买了 4,629,976 股。北方信托公司在第四季度将其在辉瑞的股份增加了 7.7%。北方信托公司目前拥有 58,382,560 股该生物制药公司的股票，价值为 1,548,889,000 美元，此前在上个季度又收购了 4,167,222 股。瑞银资产管理公司（UBS AM）在第四季度将其在辉瑞的股份增加了 3.5%。瑞银资产管理公司目前拥有 39,402,619 股该生物制药公司的股票，价值为 1,045,351,000 美元，此前在此期间又收购了 1,333,740 股。德意志银行在第一季度将其在辉瑞的股份增加了 7.0%。德意志银行目前拥有 28,239,197 股该生物制药公司的股票，价值为 715,581,000 美元，此前在上个季度又购买了 1,846,436 股。最后，高盛集团在第一季度将其在辉瑞的股份增加了 51.9%。高盛集团目前拥有 26,456,457 股该生物制药公司的股票，价值为 670,407,000 美元，此前在上个季度又购买了 9,041,990 股。机构投资者和对冲基金持有该公司 68.36% 的股份。</p>
<h2>分析师设定新目标价</h2>
<p>辉瑞成为多份研究分析报告的主题。Wolfe Research 将辉瑞的目标价从 22.00 美元上调至 23.00 美元，并在 4 月 30 日的报告中给予该公司 “表现不佳” 的评级。Cantor Fitzgerald 在 4 月 22 日的研究报告中对辉瑞进行了覆盖，设定了 “中性” 评级和 24.00 美元的目标价。美国银行在周三的研究报告中将辉瑞的目标价从 27.00 美元上调至 28.00 美元，并给予该股票 “中性” 评级。Berenberg Bank 在 5 月 29 日的研究报告中将辉瑞的目标价从 28.00 美元下调至 25.00 美元，并对该股票设定了 “持有” 评级。最后，TD Cowen 在 4 月 22 日的研究报告中将辉瑞的目标价从 32.00 美元下调至 28.00 美元，并对该公司设定了 “持有” 评级。一位分析师对该股票给予了卖出评级，十一位分析师给予了持有评级，五位分析师给予了买入评级，二位分析师给予了强烈买入评级。根据 MarketBeat.com 的数据，辉瑞目前的平均评级为 “持有”，平均目标价为 28.12 美元。</p>
<ul>
<li>5 只被低估的高分红股票，强劲的派息潜力</li>
</ul>
<p><strong>获取我们关于辉瑞的最新报告</strong></p>
<h2>辉瑞股价上涨 1.4%</h2>
<p>辉瑞股票在周五开盘价为 24.57 美元。该公司的流动比率为 1.16，速动比率为 0.96，债务与股本比率为 0.65。辉瑞的 12 个月低点为 20.92 美元，12 个月高点为 30.43 美元。该公司的 50 日移动平均价格为 24.44 美元，200 日移动平均价格为 24.50 美元。该股票的市值为 1396.9 亿美元，市盈率为 13.07，PEG 比率为 0.87，贝塔值为 0.52。</p>
<ul>
<li>辉瑞的 7.5% 股息：收入避风港还是纸牌屋？</li>
</ul>
<p>辉瑞（NYSE:PFE - 获取免费报告）最近在 8 月 5 日发布了其财报。这家生物制药公司报告季度每股收益为 0.78 美元，超出分析师一致预期的 0.58 美元，超出幅度为 0.20 美元。该公司季度收入为 146.5 亿美元，而一致预期为 134.3 亿美元。辉瑞的净利润率为 16.84%，股本回报率为 21.42%。辉瑞的季度收入较去年同期增长了 10.3%。在去年同期，该公司每股收益为 0.60 美元。整体来看，股票分析师预测辉瑞在当前年度的每股收益将达到 2.95 美元。</p>
<h2>辉瑞股息公告</h2>
<p>该公司最近还宣布了一项季度股息，将于 9 月 2 日支付。7 月 25 日的股东将获得每股 0.43 美元的股息。除息日期为 7 月 25 日。这相当于每年 1.72 美元的股息，股息收益率为 7.0%。辉瑞的股息支付比率目前为 91.49%。</p>
<h2>辉瑞公司简介</h2>
<p>（免费报告）</p>
<p>辉瑞公司在美国、欧洲及国际上发现、开发、制造、营销、分销和销售生物制药产品。该公司在多个治疗领域提供药物和疫苗，包括心血管代谢、偏头痛和女性健康，旗下品牌包括 Eliquis、Nurtec ODT/Vydura、Zavzpret 和 Premarin 系列；在满足医疗需求的传染病领域，旗下品牌包括 Prevnar 系列、Abrysvo、Nimenrix、FSME/IMMUN-TicoVac 和 Trumenba；以及 COVID-19 的预防和治疗，以及未来潜在的 mRNA 和抗病毒产品，旗下品牌包括 Comirnaty 和 Paxlovid。</p>
<h2>推荐故事</h2>
<ul>
<li>我们更看好的五只股票，胜过辉瑞</li>
<li>现在可以购买的三只沃伦·巴菲特股票</li>
<li>爱彼迎超出预期收益，但增长故事正在失去高度</li>
<li>在投资中，下调评级意味着什么？</li>
<li>Netflix 的多头与空头：谁将在这次回调中获胜？</li>
<li>有不同类型的股票可供投资</li>
<li>Viasat：为什么一大笔现金让空头们纷纷逃避</li>
</ul>
<p><strong>想看看其他对辉瑞持有股份的对冲基金吗？</strong> 访问 HoldingsChannel.com 获取辉瑞公司（NYSE:PFE - 免费报告）的最新 13F 文件和内部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVBGRQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVBGRQ"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在辉瑞吗？</h2>
<p>在考虑辉瑞之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而辉瑞并不在名单上。</p>
<p>虽然辉瑞目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

辉瑞

<p>MUFG 证券 EMEA plc 在第一季度减少了对辉瑞公司（NYSE:PFE）54.6% 的持股，目前持有 395,999 股，价值 10,035,000 美元。包括先锋集团和高盛在内的其他机构投资者也调整了在辉瑞的持仓。分析师对该股票的评级各不相同，平均目标价为 28.12 美元。辉瑞的股票开盘价为 24.57 美元，市值为 1396.9 亿美元，最近的每股收益为 0.78 美元，超过了预期</p>

<p>MUFG Securities EMEA plc lowered its position in Pfizer Inc. (NYSE:PFE - Free Report) by 54.6% during the first quarter, according to the company in its most recent disclosure with the Securities &amp; Exchange Commission. The fund owned 395,999 shares of the biopharmaceutical company's stock after selling 476,100 shares during the period. MUFG Securities EMEA plc's holdings in Pfizer were worth $10,035,000 as of its most recent filing with the Securities &amp; Exchange Commission.</p>
<div class="lb-trans"><p>根据 MUFG 证券 EMEA plc 最近向证券交易委员会的披露，该公司在 2023 年第一季度将其在辉瑞公司（NYSE:PFE - 免费报告）的持股比例降低了 54.6%。在此期间，该基金出售了 476,100 股后，持有 395,999 股该生物制药公司的股票。根据其最近向证券交易委员会的备案，MUFG 证券 EMEA plc 在辉瑞的持股价值为 10,035,000 美元。</p>
</div><ul>
<li>Healthcare Stocks Hit Valuation Bottom, 3 Names to Rebound</li>
</ul>
<div class="lb-trans"><ul>
<li>医疗保健股票估值触底，3 只股票有望反弹</li>
</ul>
</div><p>Other hedge funds and other institutional investors also recently bought and sold shares of the company. Vanguard Group Inc. grew its position in Pfizer by 0.9% during the first quarter. Vanguard Group Inc. now owns 523,165,127 shares of the biopharmaceutical company's stock valued at $13,257,004,000 after buying an additional 4,629,976 shares during the period. Northern Trust Corp boosted its stake in shares of Pfizer by 7.7% during the 4th quarter. Northern Trust Corp now owns 58,382,560 shares of the biopharmaceutical company's stock worth $1,548,889,000 after acquiring an additional 4,167,222 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in shares of Pfizer by 3.5% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 39,402,619 shares of the biopharmaceutical company's stock valued at $1,045,351,000 after acquiring an additional 1,333,740 shares during the period. Deutsche Bank AG increased its stake in shares of Pfizer by 7.0% in the 1st quarter. Deutsche Bank AG now owns 28,239,197 shares of the biopharmaceutical company's stock valued at $715,581,000 after purchasing an additional 1,846,436 shares in the last quarter. Finally, Goldman Sachs Group Inc. increased its stake in shares of Pfizer by 51.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 26,456,457 shares of the biopharmaceutical company's stock valued at $670,407,000 after purchasing an additional 9,041,990 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company's stock.</p>
<div class="lb-trans"><p>其他对冲基金和机构投资者最近也买卖了该公司的股票。先锋集团在第一季度将其在辉瑞的持股比例增加了 0.9%。先锋集团目前拥有 523,165,127 股该生物制药公司的股票，价值为 13,257,004,000 美元，此前在此期间又购买了 4,629,976 股。北方信托公司在第四季度将其在辉瑞的股份增加了 7.7%。北方信托公司目前拥有 58,382,560 股该生物制药公司的股票，价值为 1,548,889,000 美元，此前在上个季度又收购了 4,167,222 股。瑞银资产管理公司（UBS AM）在第四季度将其在辉瑞的股份增加了 3.5%。瑞银资产管理公司目前拥有 39,402,619 股该生物制药公司的股票，价值为 1,045,351,000 美元，此前在此期间又收购了 1,333,740 股。德意志银行在第一季度将其在辉瑞的股份增加了 7.0%。德意志银行目前拥有 28,239,197 股该生物制药公司的股票，价值为 715,581,000 美元，此前在上个季度又购买了 1,846,436 股。最后，高盛集团在第一季度将其在辉瑞的股份增加了 51.9%。高盛集团目前拥有 26,456,457 股该生物制药公司的股票，价值为 670,407,000 美元，此前在上个季度又购买了 9,041,990 股。机构投资者和对冲基金持有该公司 68.36% 的股份。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新目标价</h2>
</div><p>PFE has been the topic of several research analyst reports. Wolfe Research raised their price objective on Pfizer from $22.00 to $23.00 and gave the company an &#34;underperform&#34; rating in a report on Wednesday, April 30th. Cantor Fitzgerald initiated coverage on Pfizer in a research report on Tuesday, April 22nd. They set a &#34;neutral&#34; rating and a $24.00 target price on the stock. Bank of America upped their price objective on shares of Pfizer from $27.00 to $28.00 and gave the stock a &#34;neutral&#34; rating in a research report on Wednesday. Berenberg Bank dropped their target price on shares of Pfizer from $28.00 to $25.00 and set a &#34;hold&#34; rating on the stock in a research report on Thursday, May 29th. Finally, TD Cowen reduced their price target on shares of Pfizer from $32.00 to $28.00 and set a &#34;hold&#34; rating for the company in a research report on Tuesday, April 22nd. One analyst has rated the stock with a sell rating, eleven have assigned a hold rating, five have given a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, Pfizer presently has an average rating of &#34;Hold&#34; and an average target price of $28.12.</p>
<div class="lb-trans"><p>辉瑞成为多份研究分析报告的主题。Wolfe Research 将辉瑞的目标价从 22.00 美元上调至 23.00 美元，并在 4 月 30 日的报告中给予该公司 “表现不佳” 的评级。Cantor Fitzgerald 在 4 月 22 日的研究报告中对辉瑞进行了覆盖，设定了 “中性” 评级和 24.00 美元的目标价。美国银行在周三的研究报告中将辉瑞的目标价从 27.00 美元上调至 28.00 美元，并给予该股票 “中性” 评级。Berenberg Bank 在 5 月 29 日的研究报告中将辉瑞的目标价从 28.00 美元下调至 25.00 美元，并对该股票设定了 “持有” 评级。最后，TD Cowen 在 4 月 22 日的研究报告中将辉瑞的目标价从 32.00 美元下调至 28.00 美元，并对该公司设定了 “持有” 评级。一位分析师对该股票给予了卖出评级，十一位分析师给予了持有评级，五位分析师给予了买入评级，二位分析师给予了强烈买入评级。根据 MarketBeat.com 的数据，辉瑞目前的平均评级为 “持有”，平均目标价为 28.12 美元。</p>
</div><ul>
<li>Top 5 Undervalued Dividend Stocks With Strong Payout Potential</li>
</ul>
<div class="lb-trans"><ul>
<li>5 只被低估的高分红股票，强劲的派息潜力</li>
</ul>
</div><p><strong>Get Our Latest Report on PFE</strong></p>
<div class="lb-trans"><p><strong>获取我们关于辉瑞的最新报告</strong></p>
</div><h2>Pfizer Trading Up 1.4%</h2>
<div class="lb-trans"><h2>辉瑞股价上涨 1.4%</h2>
</div><p>Shares of PFE stock opened at $24.57 on Friday. The company has a current ratio of 1.16, a quick ratio of 0.96 and a debt-to-equity ratio of 0.65. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $30.43. The company's 50-day moving average price is $24.44 and its 200-day moving average price is $24.50. The stock has a market cap of $139.69 billion, a price-to-earnings ratio of 13.07, a PEG ratio of 0.87 and a beta of 0.52.</p>
<div class="lb-trans"><p>辉瑞股票在周五开盘价为 24.57 美元。该公司的流动比率为 1.16，速动比率为 0.96，债务与股本比率为 0.65。辉瑞的 12 个月低点为 20.92 美元，12 个月高点为 30.43 美元。该公司的 50 日移动平均价格为 24.44 美元，200 日移动平均价格为 24.50 美元。该股票的市值为 1396.9 亿美元，市盈率为 13.07，PEG 比率为 0.87，贝塔值为 0.52。</p>
</div><ul>
<li>Pfizer's 7.5% Dividend: Income Haven or House of Cards?</li>
</ul>
<div class="lb-trans"><ul>
<li>辉瑞的 7.5% 股息：收入避风港还是纸牌屋？</li>
</ul>
</div><p>Pfizer (NYSE:PFE - Get Free Report) last issued its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, topping analysts' consensus estimates of $0.58 by $0.20. The company had revenue of $14.65 billion for the quarter, compared to the consensus estimate of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. Pfizer's quarterly revenue was up 10.3% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.60 earnings per share. As a group, equities analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.</p>
<div class="lb-trans"><p>辉瑞（NYSE:PFE - 获取免费报告）最近在 8 月 5 日发布了其财报。这家生物制药公司报告季度每股收益为 0.78 美元，超出分析师一致预期的 0.58 美元，超出幅度为 0.20 美元。该公司季度收入为 146.5 亿美元，而一致预期为 134.3 亿美元。辉瑞的净利润率为 16.84%，股本回报率为 21.42%。辉瑞的季度收入较去年同期增长了 10.3%。在去年同期，该公司每股收益为 0.60 美元。整体来看，股票分析师预测辉瑞在当前年度的每股收益将达到 2.95 美元。</p>
</div><h2>Pfizer Dividend Announcement</h2>
<div class="lb-trans"><h2>辉瑞股息公告</h2>
</div><p>The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th will be issued a dividend of $0.43 per share. The ex-dividend date is Friday, July 25th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.0%. Pfizer's dividend payout ratio is currently 91.49%.</p>
<div class="lb-trans"><p>该公司最近还宣布了一项季度股息，将于 9 月 2 日支付。7 月 25 日的股东将获得每股 0.43 美元的股息。除息日期为 7 月 25 日。这相当于每年 1.72 美元的股息，股息收益率为 7.0%。辉瑞的股息支付比率目前为 91.49%。</p>
</div><h2>Pfizer Company Profile</h2>
<div class="lb-trans"><h2>辉瑞公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.</p>
<div class="lb-trans"><p>辉瑞公司在美国、欧洲及国际上发现、开发、制造、营销、分销和销售生物制药产品。该公司在多个治疗领域提供药物和疫苗，包括心血管代谢、偏头痛和女性健康，旗下品牌包括 Eliquis、Nurtec ODT/Vydura、Zavzpret 和 Premarin 系列；在满足医疗需求的传染病领域，旗下品牌包括 Prevnar 系列、Abrysvo、Nimenrix、FSME/IMMUN-TicoVac 和 Trumenba；以及 COVID-19 的预防和治疗，以及未来潜在的 mRNA 和抗病毒产品，旗下品牌包括 Comirnaty 和 Paxlovid。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than Pfizer</li>
<li>3 Warren Buffett Stocks to Buy Now</li>
<li>Airbnb Beats Earnings, But the Growth Story Is Losing Altitude</li>
<li>What Does Downgrade Mean in Investing?</li>
<li>Netflix Bulls vs. Bears: Who Wins This Pullback?</li>
<li>There Are Different Types of Stock To Invest In</li>
<li>Viasat: Why a Wall of Cash Has Shorts Running for Cover</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过辉瑞</li>
<li>现在可以购买的三只沃伦·巴菲特股票</li>
<li>爱彼迎超出预期收益，但增长故事正在失去高度</li>
<li>在投资中，下调评级意味着什么？</li>
<li>Netflix 的多头与空头：谁将在这次回调中获胜？</li>
<li>有不同类型的股票可供投资</li>
<li>Viasat：为什么一大笔现金让空头们纷纷逃避</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding PFE?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对辉瑞持有股份的对冲基金吗？</strong> 访问 HoldingsChannel.com 获取辉瑞公司（NYSE:PFE - 免费报告）的最新 13F 文件和内部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVBGRQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=PFE"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Pfizer Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在辉瑞吗？</h2>
</div><p>Before you consider Pfizer, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑辉瑞之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而辉瑞并不在名单上。</p>
</div><p>While Pfizer currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然辉瑞目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

MUFG Securities EMEA plc Trims Holdings in Pfizer Inc. (NYSE:PFE)

- MUFG Securities EMEA plc 在第一季度将 Pfizer Inc.的持股减少 54.6%。  
- Vanguard Group Inc.和其他机构投资者在同一时期增持 Pfizer 股份。  
- Pfizer 报告第二季度每股收益为 0.78 美元，超出分析师预期。  

MUFG 证券 EMEA 有限公司减少了其在辉瑞公司（NYSE:PFE）的持股量